Assetmark Inc. Boosts Holdings in Abbott Laboratories $ABT

Key Points

• Assetmark Inc. increased its stake in Abbott Laboratories by 8.9% in the first quarter, adding 16,506 shares and bringing its total holdings to 202,552 shares worth about $20.8 million.
• Abbott reported better-than-expected Q2 earnings, with EPS of $1.31 topping estimates and revenue up 13% year over year, while also raising its full-year 2026 EPS guidance to $5.45-$5.60.
• Wall Street sentiment remains constructive: analysts have a Moderate Buy consensus on the stock, and several firms recently lifted or reaffirmed bullish price targets after the earnings update.

Assetmark Inc. grew its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 8.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 202,552 shares of the healthcare product maker's stock after purchasing an additional 16,506 shares during the period. Assetmark Inc.'s holdings in Abbott Laboratories were worth $20,796,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. MidAtlantic Capital Management Inc. bought a new stake in Abbott Laboratories during the 4th quarter valued at approximately $25,000. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories in the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories in the fourth quarter worth $26,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

Wall Street Analyst Weigh In

ABT has been the subject of a number of research reports. JPMorgan Chase & Co. increased their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the stock an "overweight" rating in a report on Friday. Barclays decreased their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating for the company in a research note on Monday, April 20th. Leerink Partners lowered their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a "market perform" rating for the company in a research report on Tuesday, April 21st. Raymond James Financial dropped their price objective on shares of Abbott Laboratories from $130.00 to $115.00 and set an "outperform" rating on the stock in a research note on Friday, April 17th. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $130.00 price objective on shares of Abbott Laboratories in a report on Friday. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $118.61.

Abbott Laboratories Trading Up 1.9%

Abbott Laboratories stock opened at $100.71 on Friday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The business's fifty day moving average is $89.89 and its 200 day moving average is $102.17. The stock has a market capitalization of $175.41 billion, a PE ratio of 32.59, a price-to-earnings-growth ratio of 1.73 and a beta of 0.61. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.51 billion for the quarter, compared to analysts' expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The business's revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories's dividend payout ratio is 70.59%.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction dated Thursday, April 23rd. The shares were purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares of the company's stock, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Daniel J. Starks purchased 10,000 shares of the company's stock in a transaction dated Monday, April 27th. The stock was purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.46% of the company's stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.